Alumis Signs a Definitive Merger Agreement with ACELYRIN to Develop Novel Therapies for Immune-mediated Diseases
Shots:
- Alumis & ACELYRIN have entered into a definitive agreement to merge, with ACELYRIN stockholders receiving 0.4274 Alumis shares/share, owning 45% of the combined entity - "Alumis"; closing expected in Q2’25
- As of Dec 31, 2024, Alumis & ACELYRIN had ~$289M & ~$448M in cash as well as investments, respectively, with a pro forma total of ~$737M to fund clinical trials & operations into 2027
- Merged pipeline incl. Alumis’ ESK-001 (P-III ONWARD topline data for PsO in H1’26, P-IIb LUMUS topline data for SLE in 2026, & 52wk. P-II OLE update in 2025) & A-005 (P-II trial in MS starting H2’25 with topline data in 2026), plus ACELYRIN’s lonigutamab (P-II trial showing robust efficacy in TED; development plan is under evaluation)
Ref: Alumis | Image: Alumis & ACELYRIN
Related News:- Zimmer Biomet to Acquire Paragon 28 for ~$1.2B
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Ridhi is an avid secondary researcher who follows trends in the biopharmaceutical and healthcare sectors to curate engaging content for the global audience. She works as a news editor at PharmaShots and loves to read books and explore new destinations.
